TREMFYA® (guselkumab) demonstrated sustained clinical and endoscopic remission through 3 years in moderately to severely active Crohn's disease
Johnson & Johnson announced three-year (Week 144) long-term extension data from the Phase 3 GALAXI 2 and 3 studies showing TREMFYA (guselkumab) sustained clinical remission in up to 94% of adults with moderately to severely active Crohn's disease. Endoscopic remission was achieved by 52-61% of patients depending on dosing regimen, and 88% achieved 90-day corticosteroid-free clinical remission, with 74% of patients remaining on treatment through three years and a safety profile consistent with prior data.
Key figures
- Drug Name
- TREMFYA (guselkumab)
- Phase Of Trial
- Phase 3
- Study week
- 144
- Trial names
- ["GALAXI 2","GALAXI 3"]
- Retention through 3 years
- 74%
- Clinical remission 100mg q8w
- 94%
- Clinical remission 200mg q4w
- 91%
- Corticosteroid free remission
- 88%
- Endoscopic remission 100mg q8w
- 52%
- Endoscopic remission 200mg q4w
- 61%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.